The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of AST-120 (Kremezin) in Patients With Moderate to Severe CKD
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Cited by
p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease
Wu, I.-W., Hsu, K.-H., Lee, C.-C., Sun, C.-Y., Hsu, H.-J., Tsai, C.-J., Tzen, C.-Y., Wang, Y.-C., Lin, C.-Y., & Wu, M.-S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq580 · Cited by 510
Uremic toxins originating from colonic microbial metabolism
Evenepoel, P., Meijers, B. K. I., Bammens, B. R. M., & Verbeke, K. (2009) · Kidney International · doi:10.1038/ki.2009.402 · Cited by 445
Liabeuf, S., Barreto, D. V., Barreto, F. C., Meert, N., Glorieux, G., Schepers, E., Temmar, M., Choukroun, G., Vanholder, R., Massy, Z. A., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp592 · Cited by 431
Gryp, T., Vanholder, R., Vaneechoutte, M., & Glorieux, G. (2017) · Toxins · doi:10.3390/toxins9020052 · Cited by 417
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target
Ramezani, A., Massy, Z. A., Meijers, B., Evenepoel, P., Vanholder, R., & Raj, D. S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.027 · Cited by 394
“The oral sorbent AST120 was found to decrease plasma IS levels in a dose-dependent manner.(146) The primary effect of AST-120 appears to be mediated through its adsorption of urea-derived ammonia and interruption of enterohepatic urea recycling.”
BackgroundThe gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression
Meijers, B. K. I., & Evenepoel, P. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq818 · Cited by 328
Yu, M., Kim, Y. J., & Kang, D.-H. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05340610 · Cited by 314
The Impact of CKD on Uremic Toxins and Gut Microbiota
Rysz, J., Franczyk, B., Ławiński, J., Olszewski, R., Ciałkowska-Rysz, A., & Gluba-Brzózka, A. (2021) · Toxins · doi:10.3390/toxins13040252 · Cited by 307
Evenepoel, P., Poesen, R., & Meijers, B. (2017) · Pediatric Nephrology · doi:10.1007/s00467-016-3527-x · Cited by 305
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD
Schulman, G., Berl, T., Beck, G. J., Remuzzi, G., Ritz, E., Arita, K., Kato, A., & Shimizu, M. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010042 · Cited by 282
Self-citationKovesdy, C. P., Kopple, J. D., & Kalantar-Zadeh, K. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.036418 · Cited by 281
Indoxyl Sulfate—Review of Toxicity and Therapeutic Strategies
Leong, S., & Sirich, T. (2016) · Toxins · doi:10.3390/toxins8120358 · Cited by 272
Gut microbiome and kidney disease: a bidirectional relationship
Al Khodor, S., & Shatat, I. F. (2017) · Pediatric Nephrology · doi:10.1007/s00467-016-3392-7 · Cited by 191
“sulfate levels and a decrease in uremia-related malaise [85].”
BackgroundGut microbiota–derived short-chain fatty acids and kidney diseases
Li, L., Ma, L., & Fu, P. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s150825 · Cited by 164
Yamamoto, S., Zuo, Y., Ma, J., Yancey, P. G., Hunley, T. E., Motojima, M., Fogo, A. B., Linton, M. F., Fazio, S., Ichikawa, I., et al. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq759 · Cited by 74
“Although AST-120 has currently not been shown to decrease incidence of doubling of serum creatinine in humans [13], a Phase 3 clinical trial is underway to examine its effects on the composite end point of serum creatinine elevation or progression to transplant or dialysis [9].”
BackgroundIto, S., Higuchi, Y., Yagi, Y., Nishijima, F., Yamato, H., Ishii, H., Osaka, M., & Yoshida, M. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0112023 · Cited by 72
Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
Yamaguchi, J., Tanaka, T., & Inagi, R. (2017) · Nephron · doi:10.1159/000453673 · Cited by 60
Metadata
- Authors
- Schulman, G., Agarwal, R., Acharya, M., Berl, T., Blumenthal, S., & Kopyt, N.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2006-04
- Volume
- 47
- Issue
- 4
- Pages
- 565-577
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2133991735
- Cited by
- 200
- References
- 5
- FWCI
- 3.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.